Sjogren’s Sensory Neuropathy: A Potentially Treatable Condition with Early Intervention

Objective To describe 2 cases of Sjögren's syndrome sensory neuronopathy (SSSN) in which early intervention resulted excellent clinical outcomes. Background Acquired neuronopathies (i.e. dorsal root ganglionopathies) are rare neuropathies most commonly associated with (SS) and paraneoplastic syndromes. Design/Methods We patients who presented painful symptoms, sicca symptoms positive SSA antinuclear antibodies. The first patient perceived symmetric hand weakness (despite no motor nerve conduction abnormalities), total body numbness paresthesia, as well ataxia, while the other asymmetric pain left foot hand. electrophysiological profiles varied considerably between patients. demonstrated complete absence action potentials (SNAPs) whereas second had only asymmetrical superficial peroneal sural SNAPs, corresponding his deficit. was diagnosed SSSN, neuropathy SS. treated mycophenolate mofetil (MMF) dramatic symptomatic improvement near recovery deficits. prednisone, methotrexate, ultimately switched to MMF rituximab significant symptoms. Results NA. Conclusions SS is including neuronopathies. Both met diagnostic criteria for though differing severities. date, there has been randomized controlled trial evaluating treatments SSSN. However, our findings suggest that use could result considerable benefit a disease often functionally devastating.